Advertisement
MedImmune
Subscribe to MedImmune

The Lead

AstraZeneca Advances Tralokinumab for Severe Asthma to Phase III

August 14, 2014 8:32 am | News | Comments

AstraZeneca announced the start of the Phase III program for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm.  

MedImmune Fights Pediatricians' New Advice

July 28, 2014 8:11 am | by LINDSEY TANNER, AP Medical Writer | News | Comments

A costly drug given mostly to premature babies is at the center of a clash between the...

MedImmune and Advaxis Partner on Immuno-Oncology Combination Clinical Trial

July 22, 2014 8:20 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm,...

Incyte and MedImmune to Collaborate on Immuno-Oncology Combination Clinical Trial

May 14, 2014 8:06 am | News | Comments

The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s...

View Sample

FREE Email Newsletter

MedImmune and Immunocore to Develop Novel Cancer Therapies

January 8, 2014 8:25 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company.

AstraZeneca's MedImmune Acquires Spirogen - Boosts Antibody-Drug Conjugate Capability

October 15, 2013 8:51 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology. MedImmune has also entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADC Therapeutics’ antibody-drug conjugate programmes in preclinical development.

MedImmune Strengthens Immune-Mediated Cancer Therapy Portfolio with Acquisition of Amplimmune

August 26, 2013 9:04 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.

Advertisement

MedImmune, AstraZeneca’s Biologics Arm, and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity

June 17, 2013 8:06 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM’s enteroendocrine cell (EEC) program for the treatment of type 2 diabetes and obesity.

MedImmune, AstraZeneca’s Biologics Unit, Acquires AlphaCore Pharma

April 3, 2013 8:08 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development unit, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.

MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from Pfizer

October 3, 2011 4:11 am | News | Comments

MedImmune, the global biologics arm of AstraZeneca, today announced execution of an in-licensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody.

U.S. Approves Flu Vaccine for Coming Season

July 18, 2011 1:01 pm | News | Comments

The U.S. Food and Drug Administration said Monday it has approved the new flu vaccine for the season beginning this year.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading